Clinical trialNCT07342439Not, yet, recruitingPhase 3Interventional

Study of Serine Supplementation to Protect Vision in MacTel

SponsorThe Lowy Medical Research Institute LimitedEnrollment120Macular Telangiectasia Type 2 (MacTel)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this clinical trial is to look at the efficacy and safety of giving oral serine (an amino acid) on the progression of structural and functional changes of the retina in people with MacTel type 2. The main questions it aims to answer are: * Does serine slow the progression of MacTel? * Is long-term serine supplementation safe in people with MacTel? Researchers will compare serine to a placebo (a look-alike substance that contains no drug) to see if serine works to slow the progression of MacTel. Participants will: * Take serine or a placebo twice a day for 24 months * Visit the clinic once every 6 months for eye exam, eye imaging and blood tests * Keep a diary of their symptoms, missed doses, and changes in medications

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Save Sight Institute
Sydney, New South Wales, Australia
Elisa Cornish, MD
Cerulea- Rveeh
Melbourne, Victoria, Australia
Robyn Guymer, MD

Germany

University of Bonn
Bonn, Germany
Kristina Pfau, MD
University of Freiburg, Department of Ophthalmology
Freiburg im Breisgau, Germany
Felicitas Bucher, MD
St. Franziskus Hospital
Münster, Germany
Clemens Lange, MD

Netherlands

Radboud University Medical Center
Nijmegen, Netherlands
Suzanne Yzer, MD

United Kingdom

Moorfields Eye Hospital
London, United Kingdom
Cathy Egan, MD
Oxford Eye Hospital
Oxford, United Kingdom
Samantha de Silva, MD

United States

Hamilton Glaucoma Center- Ucsd
La Jolla, California, United States
Chrisopher Toomey, MD, PhD
University of Michigan, Kellogg Eye Center
Ann Arbor, Michigan, United States
Grant Comer, MD
Retina Associates of Cleveland, Inc.
Cleveland, Ohio, United States
LAWRENCE SINGERMAN, MD
University of Utah Health Care, Moran Eye Center
Salt Lake City, Utah, United States
Paul Bernstein, MD, PhD

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Serine

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Sept 2026
Primary completion: 30 Nov 2029
Completion: 28 Feb 2030
Last update posted: 15 Jan 2026
Registered enrollment: 120
Registry id: NCT07342439

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.